Malignant Melanoma
📧 Sign up to get email alerts when something new happens for Malignant Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study [Phase 3]
This Phase 3 trial update reports safety and efficacy results for pembrolizumab plus lenvatinib as first-line therapy in adults with advance…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma [Phase 2]
Phase 2 trial evaluating L-TIL plus tislelizumab as first-line treatment for advanced malignant melanoma was terminated.
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: Fast Track Diagnosis of Skin Cancer by Advanced Imaging [NA]
A clinical trial evaluating fast-track diagnosis of skin cancer using advanced imaging has completed.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma [Phase 3]
A Phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab to standard adjuvant nivolumab in macroscopic Stage III melanoma is active-n…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus lenvatinib as first-line therapy for advanced melanoma has completed and posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab [Phase 2]
Phase 2 trial update evaluating optimal neo-adjuvant combination therapy with ipilimumab and nivolumab for malignant melanoma stage III.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer [NA]
This ClinicalTrials.gov record reports a completed study evaluating tissue and hematopoietic/mesenchymal stem cells in humanized xenograft m…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Efficacy Study of IL-21 to Treat Metastatic Melanoma [Phase 2]
Phase 2 efficacy study of IL-21 for metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma [Phase 2]
Phase 2 clinical trial update evaluating interleukin-21 for metastatic or recurrent malignant melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma [Phase 2]
Phase 2 clinical trial evaluating perifosine in patients with metastatic or recurrent malignant melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 [Phase 1, Phase 2]
A long-term follow-up study of participants from a previous Phase I/II trial in malignant melanoma has terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. [Phase 4]
Phase IV clinical trial update evaluating ipilimumab in patients with advanced malignant melanoma.
-
FDA approval · 2023-03-16FDA Approved: TAFINLAR — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved TAFINLAR (dabrafenib) under an Original Application for patients with unresectable or metastatic melanoma harboring a BRAF V600…
-
FDA approval · 2023-03-16FDA Approved: MEKINIST — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved MEKINIST (trametinib) in its original application for unresectable or metastatic melanoma with BRAF V600E or V600K mutations (i…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors [Phase 1]
Phase 1 trial update on an arginase-1 peptide vaccine in patients with metastatic solid tumors, including non-small cell lung cancer and uro…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma [Phase 2]
Phase 2 trial investigating recombinant human adenovirus type 5 injection with a PD-1 monoclonal antibody and nab-paclitaxel for liver metas…
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma [Phase 2]
Phase 2 clinical trial evaluating tumor-infiltrating lymphocytes after combination chemotherapy in metastatic melanoma; results posted but n…
-
FDA approval · 2022-10-28FDA Approved: COTELLIC — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for COTELLIC (cobimetinib) from Genentech, expanding its labeling. The action relates to the tre…
-
CLINICAL_TRIALS trial_result · 2022-06-15Clinical Trial Update: This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) [Phase 2]
Phase II study evaluating AZD6738 in combination with durvalumab in gastric adenocarcinoma and malignant melanoma (Cohort A: gastric cancer …
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating immunization with 8 peptides plus CpG 7909 or Montanide ISA51 in metastatic cutaneous melanoma; study status term…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy [Phase 1, Phase 2]
Clinical trial update for 4SC-202 in combination with pembrolizumab in patients with malignant melanoma who are primary refractory or non-re…
-
FDA approval · 2021-11-03FDA Approved: ISOSULFAN BLUE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original application for Isosulfan Blue, a surgical dye used to identify sentinel lymph nodes during …
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: PLX3397 KIT in Acral aNd mucOsal Melanoma [Phase 2]
Phase 2 trial update for PLX3397 (KIT inhibitor) in acral and mucosal melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating MAGE-3.A1 peptide vaccine with CpG 7909 adjuvant in metastatic melanoma has been terminated; results p…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma [Phase 1]
Phase 1 study evaluating safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV malignant melanoma has completed …